Rainer Westermann

Rainer Westermann

Rainer Westermann is the Chairman of the Life Sciences Acceleration Alliance e.V., Munich, a European non-profit coalition dedicated to educating and conveying knowledge about venture capital financing in the life sciences sector in Europe. LSAA aims to improve the entrepreneurial environment for young and innovative companies in life sciences in Europe and to create a reliable legal framework for corresponding investments and venture capitalists.

Rainer is a Board Member and former President of the Crisis Protection Network, Zurich, an international network of reputation management advisors. He serves on the Advisory Board of the TUM Institute for LifeLong Learning, Munich, as well as teaching as a lecturer at the TUM School of Management.

As Principal of Westermann Advisors, Rainer advises and supports clients in situations with a high reputation risk, focusing on strategic communications, reputation management and crisis as well as litigation response.

During his career, he was advisor to senior management for a broad range of blue-chip companies in Germany, Canada and the USA. He managed professional services firms and, as a corporate officer, was responsible for building, improving and protecting corporate reputation.

As Corporate Vice President of Infineon Technologies, a German DAX 30 corporation, he was responsibile for the corporate brand, marketing communications, government relations as well as external and internal communications. He was named CEO Germany for FleishmanHillard and later Burson-Marsteller, two of the leading international communications consultancies.

Rainer spent six years in North America, where he was a Member of the Management Board of LHS Group, an Atlanta based NASDAQ and Neuer Markt listed software company. He represented the company as corporate spokesperson towards the global investment community and the media. In Toronto, he built a successful corporate communications and investor relations practice for FleishmanHillard Canada. He joined the consultancy originally in Frankfurt, when he founded Fleishman-Hillard Germany, a joint venture formed from his own marketing communications agency. During his career, Rainer supported a number of clients in the health care sector and worked in-house for the medical products division of DuPont.

Rainer Westermann is the Chairman of the Life Sciences Acceleration Alliance e.V., Munich, a European non-profit coalition dedicated to educating and conveying knowledge about venture capital financing in the life sciences sector in Europe. LSAA aims to improve the entrepreneurial environment for young and innovative companies in life sciences in Europe and to create a reliable legal framework for corresponding investments and venture capitalists.

Rainer is a Board Member and former President of the Crisis Protection Network, Zurich, an international network of reputation management advisors. He serves on the Advisory Board of the TUM Institute for LifeLong Learning, Munich, as well as teaching as a lecturer at the TUM School of Management.

As Principal of Westermann Advisors, Rainer advises and supports clients in situations with a high reputation risk, focusing on strategic communications, reputation management and crisis as well as litigation response.

During his career, he was advisor to senior management for a broad range of blue-chip companies in Germany, Canada and the USA. He managed professional services firms and, as a corporate officer, was responsible for building, improving and protecting corporate reputation.

As Corporate Vice President of Infineon Technologies, a German DAX 30 corporation, he was responsibile for the corporate brand, marketing communications, government relations as well as external and internal communications. He was named CEO Germany for FleishmanHillard and later Burson-Marsteller, two of the leading international communications consultancies.

Rainer spent six years in North America, where he was a Member of the Management Board of LHS Group, an Atlanta based NASDAQ and Neuer Markt listed software company. He represented the company as corporate spokesperson towards the global investment community and the media. In Toronto, he built a successful corporate communications and investor relations practice for FleishmanHillard Canada. He joined the consultancy originally in Frankfurt, when he founded Fleishman-Hillard Germany, a joint venture formed from his own marketing communications agency. During his career, Rainer supported a number of clients in the health care sector and worked in-house for the medical products division of DuPont.

Articles: Rainer Westermann

European Life Sciences: Time for Change on Valuing Innovation

Europe / Rainer Westermann offers a sobering take on Europe’s declining global status as both a source and recipient of biopharmaceutical innovation. He argues that the time for a paradigm shift in how the EU values innovation is now, calling for pricing system reform, speedier regulatory and HTA procedures, manufacturing investments, and private capital mobilisation to reverse…

The US–EU Trade Deal: Protecting European Life Sciences Innovation in a New Era of Uncertainty

Europe / Rainer Westermann of European life science venture capital lobby group, the Life Sciences Acceleration Alliance, lays out a policy roadmap for how innovative European pharma can continue to grow and thrive against a backdrop of trade uncertainty and precarious US-EU relations.   The US/EU trade deal was presented as necessary to avoid an escalating trade…

What’s Ahead for EU Life Sciences VC Investors in 2025?

Germany / Rainer Westermann, chairman of the Life Sciences Acceleration Alliance e.V. looks out over the choppy waters for life sciences venture capitalists in Europe over 2025. Three key initiatives stand to reshape the continent’s investment climate, but broader geopolitical winds – especially those now emanating from the White House – could derail any progress.   Accepted…

EU Pharma Legislation: An Opportunity to Rethink

Europe / Rainer Westermann of venture capitalist coalition Life Sciences Acceleration Alliance reviews the potential impact of the EU’s general pharmaceutical legislation on the investment climate for the EU life sciences sector. Building on his insights from last year, Westermann urges stakeholders to seize the opportunity caused by a delay in the upcoming EU parliamentary elections to…

EU Pharma Reform: A Medicine with Serious Side Effects 

Europe / Rainer Westermann, chairman of the Life Sciences Acceleration Alliance e.V. (LSAA), which lobbies on behalf of European venture capitalists in the life sciences space, critiques the draft EU Pharma Regulation from a VC perspective, arguing that the continent’s status as a medical innovation hub is at risk if the EU Commission continues to fail to…

EU Drug Shortage is a Result of Over-Regulation & Focus on Cost Cutting 

Europe / Rainer Westermann, chairman of the Life Sciences Acceleration Alliance e.V. (LSAA), which lobbies on behalf of European venture capitalists in the life sciences space, launches a critique of current pharmaceutical policies across the EU, arguing that constant cost-containment measures, over-regulation, and bureaucracy are leading to drug shortages and acting as a bottleneck for the continent’s…

See more